Neurocrine Biosciences Inc
(NAS:NBIX)
$
126.75
0.16 (0.13%)
Market Cap: 12.83 Bil
Enterprise Value: 11.86 Bil
PE Ratio: 33.98
PB Ratio: 4.72
GF Score: 85/100 Neurocrine Biosciences Inc at Morgan Stanley Healthcare Conference Transcript
Sep 10, 2019 / 03:10PM GMT
Release Date Price:
$95.18
(-4.82%)
Jeff Hung
Morgan Stanley, Research Division - Equity Analyst
(technical difficulty)
to the Morgan Stanley Global Healthcare Conference. I'm Jeff Hung, one of the biotech analysts. Before we start, please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at www.morganstanley.com/researchdisclosures or at the registration desk.
For this session, we have Kevin Gorman, CEO of Neurocrine Biosciences. Welcome.
Kevin C. Gorman
Neurocrine Biosciences, Inc. - CEO & Director
Thank you, Jeff, and thank you to Morgan Stanley for giving us the opportunity to present today.
Jeff Hung;Kevin C. Gorman
Morgan Stanley, Research Division - Equity Analyst;Neurocrine
Definitely. For those in the room who may not be as familiar with Neurocrine, can you provide a brief introduction?
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot